Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (68 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Professor Coombs SomaScan Webinar
View:
Post by Eoganacht on Aug 21, 2020 1:50pm

Professor Coombs SomaScan Webinar

WHAT CAN PROTEOMICS TEACH US ABOUT INFECTIOUS DISEASE? | WEBINAR
 
Dr. Kevin Coombs has authored six different publications (2 pending) describing the use of the SomaScan Assay to investigate human cellular protein alterations in tissue culture in response to infection by Zika virus and various strains of influenza. In this webinar, Dr. Coombs will summarize the major findings produced from these studies and comment on how the SomaScan Assay could be used to further study infectious disease, including the current COVID-19 pandemic, in the immediate future.
 
ABSTRACT
 
Dr. Coomb’s group has used the SomaScan assay to screen >1300 host proteins in Zika virus-infected cells, both globally and specifically in the central nervous system. Significant findings include the identification of nearly 300 astrocyte proteins that were significantly dysregulated by Zika infections, pointing to pathways that may be involved in neurological complications resulting from Zika, such as microcephaly and Guillain-Barr syndrome.
 
Dr. Coombs’ work in influenza has included extensive proteomic scanning of H5N1, H1N1, and H7N9 in various cell types including induced-pluripotent stem cells. Significant findings include the observation that low-pathogenicity strains induce less profound changes to the global proteome. For instance, avian strains stimulate significant downregulation of key proteins, including those involved in antimicrobial response. Seasonal strains do not elicit the same response. Further, Dr. Coombs’ team found that viral infection in stem cells can reduce pluripotency, activate autophagy, and lead to abnormal differentiation.
 
Key highlights include:
 
- using proteomics to identify biological processes associated with infection
- measuring proteomic changes in response to antimicrobials
- comparing and contrasting cellular response to Zika and influenza 
- exploring how the SomaScan Assay could be used to study COVID-19



KEVIN COOMBS PH.D.
PROFESSOR OF MEDICAL MICROBIOLOGY WITH CROSS-APPOINTMENTS IN PHYSIOLOGY, PATHOPHYSIOLOGY, AND MICROBIOLOGY
THE UNIVERSITY OF MANITOBA
 
Dr. Kevin Coombs is a Professor in the Department of Medical Microbiology with cross-appointments in Physiology and Pathophysiology and in Microbiology. He serves on several Cell Biology, Molecular Biology, and Virology Editorial Boards and is currently Chair of the CIHR Virology & Viral Pathogenesis Committee.
 
Dr. Coombs received his B.A.s in Biology and English from the State University of New York in Geneseo and his M.A. and Ph.D. from the University of Texas in Austin. His post-doctoral training in molecular and structural virology was done in the labs of Drs. Bernie Fields and Steve Harrison at Harvard.
 
His research interests include delineation of the protein and nucleic acid interactions in nucleoprotein complexes, using a variety of RNA viruses as models. His lab studies how these interactions change as a result of, and in turn, are modulated by, conformational transitions that occur during macromolecular assembly and disassembly, how these processes can be attenuated by anti-viral compounds, and how these processes in virus infections contribute to pathogenesis in the host.
 
Comment by investclub on Aug 21, 2020 2:08pm
THanks Eoganacht  Wouldn't that be incredible if Theralase 6 months down the road were to announce a breakthrough in cancer destruction & a new way to combat Covid-19 along with other viruses!
Comment by NorCalTommy on Aug 21, 2020 10:55pm
Investclub- yes, that would be incredible if Theralase announced a breakthrough in cancer therapy AND a Covid-19 application!!!  I'd bet that the stock would probably SOAR to over .20 USD with all of that breakthrough news!!!    Geeeeeez Louise...... WTF is it going to take to move this sluggo snail machine??? NCT
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 68 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250